Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)

Company Overview - Fulgent Genetics, Inc. (NASDAQ: FLGT) is a leading provider of comprehensive genetic testing solutions, primarily serving healthcare providers, researchers, and individuals in the United States [1] - The company specializes in next-generation sequencing (NGS) technology, which enables advanced genetic analysis [1] Investment Analysis - The Stock Research Platform (SRP) is focused on identifying companies with strong balance sheets, sustainable growth pathways, and attractive valuations that present significant upside potential with limited downside risk [1] - The analysis reflects the author's personal opinions and is not intended as investment advice, emphasizing the importance of individual due diligence [1] Analyst Position - The analyst has a beneficial long position in the shares of FLGT, indicating confidence in the company's future performance [2]